Kornimate/medical-research-clean huggingface dataset:
mechanism of insulin-resistant in lean non-diabetics

Conditions: Insulin Resistance; Insulin Sensitivity; Type 2 Diabetes

Summary: the study is designed to test the following primary hypothesis: * aerobic exercise training will improve insulin sensitivity in insulin resistant subjects through changes in the major cellular signaling pathways and and/or their regulators. accordingly, the proposed study is designed to accomplish the following specific aims: * quantitate how exercise training improves insulin sensitivity and decreases cardiovascular risk factors in a general population of lean, nondiabetic, insulin resistant subjects. effects on known cardiovascular risk factors including blood pressure and serum lipoproteins will be evaluated. change in regional adiposity will also be measured * determine the effects of a program of regular aerobic exercise on in the insulin receptor signaling pathway. biopsies of vastus lateralis muscle from insulin resistant subjects will be obtained before and after a hyperinsulinemic glucose clamp. this procedure will take place in the untrained state and after exercise training. the investigators will measure changes in the insulin receptor and the activity of the major components of the intracellular insulin signaling pathway. the investigators will also look intracellular proteins that regulate this signaling pathway.


Eligibility criteria:
inclusion criteria: * men and women aged 20-50 * no regular exercise for past 2 years exclusion criteria: * diabetes, cardiovascular disease, pregnant or lactating females,bmi \>27 * medications that may interfere with carbohydrate metabolism - glucocorticoids, adrenergic agonists, ace inhibitors, alpha blockers, diuretics, beta blockers, oral contraceptives, hmg coa reductase inhibitors * history of epilepsy, cancer, hepatitis, active infection, active graves' disease, cystic fibrosis, sickle cell anemia, peripheral vascular disease, cerebrovascular disease, asthma * any medical condition that in the opinion of the investigator will interfere with safe completion of the trial * inability to give informed consent * prior participation in a clinical trial that could potentially alter insulin sensitivity: e.g., use of new insulin sensitizers * hiv seropositive * anemia (hgb \< 12 g/dl)
extracorporeal shockwave and myofascial release therapy in chronic pelvic pain syndrome

Conditions: Chronic Pelvic Pain Syndrome

Summary: the primary aims of this research are three folds: (1) to identify more relatively effective interventions for improving pain symptoms in cp/cpps patients. (2) to ascertain the correlation between pfm elastic modulus and tenderness symptoms. this may find a more objective method of assessing efficacy. (3) to determine the correlation between the intensity of the sympathetic response and the patient's symptoms and to explore other possible pathogenetic mechanisms.

chronic prostatitis/chronic pelvic pain syndrome is a high prevalent syndrome. previous studies showed that extracorporeal shockwave therapy and myofascial release therapy could improve quality of life in patients with chronic prostatitis/chronic pelvic pain syndrome (cp/cpps). theoretically, a combined therapy with extracorporeal shockwave therapy and myofascial release therapy is likely to have significant advantages in treating cp/cpps.

Eligibility criteria:
inclusion criteria: * ① according to the national institutes of health classification of prostatitis\[27\], all male patients meet the diagnostic criteria for chronic prostatitis type iiib/chronic pelvic pain syndrome (pain in the bladder, groin, perineal area, genitalia or lower abdomen with no significant abnormalities on urological examination); * patients are aged 20-40 years; * patients with chronic pelvic pain lasting over 6 months； ④ patients sign the informed consent form. exclusion criteria: * ① patients with significant coagulation disorders, perineal anatomical abnormalities, hormonal abnormalities and neurological abnormalities; * patients with a clear cause of pelvic pain, such as a history of previous surgery, chronic infection, trauma, prostatitis and epididymitis; * patients receiving other treatments during the study; ④ patients with any urethral pathology; * patients who have had closed lumbar injections and previous lumbar surgery within six months; * patients with other conditions causing pelvic pain; ⑦ patients with contraindications to physiotherapy; ⑧ bmi\>22.9

Keywords: chronic pelvic pain syndrome extracorporeal shockwave myofascial release therapy surface electromyography sympathetic skin response
prediction of pain after total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: despite improvements in treatment, a significant part of patients have severe pain following knee arthroplasty. preoperative identification of high-risk patients would allow for an intensive individualized analgesic treatment pre- and postoperatively and thus potentially in reduced pain acute and chronically.


Eligibility criteria:
inclusion criteria: * primary unilateral tka * caucasian * 50 - 80 years * osteoarthritis exclusion criteria: * deficient written or spoken danish * impairment from psychological og neurological disease * expected discharged to rehabilitation facility * anticoagulant therapy * allergies to analgesic treatment * hypertension (systolic \> 160 / diastolic \> 100) * asa class ≥ 4
the role of willingness of participation in cardiology trials on the survival of patients

Conditions: Myocardial Infarction; Chronic Heart Failure

Summary: it has been shown retrospectively that participation and even the willingness improves the survival of patients after myocardial infarction or heart failure. we aimed to prospectively analyse the role of participation in cardiology trials on the survival of patients in a high volumen tertiary center.


Eligibility criteria:
inclusion criteria: * hospitalisation due to acute myocardial infarction, and or heart failure * singed informed consent exclusion criteria: * previous participation in any clinical study * haemodinamically instable, shock, intubation * pregnancy, breast feeding
treatment options for pediatric chronic pain: how do we best disseminate our scientific findings

Conditions: Pediatric Chronic Pain

Summary: pediatric chronic pain is a prevalent condition with manifold treatment options. however, knowledge of targeted dissemination of intervention research findings is currently lacking. the aim of this project is to determine satisfaction with current knowledge transfer from science to clinical practice amongst health care professionals, adolescents with cpp and their parents and to understand what treatment options have been offered to patients in swiss pain centers three focus groups, one with health care professionals, one with adolescent patients, and one with their parents, will be conducted to determine how the dissemination of scientific evidence to clinical practice can be improved and what hurdles exists when gathering information about pain interventions. in addition, patients will be asked about the treatment options offered to them and health care professionals about which treatments they routinely prescribe and why.


Eligibility criteria:
inclusion criteria: adolescent group: * adolescents suffering from chronic pain (i.e., persistent or recurrent pain for three months or more) * able to read and speak german parent group: * parents of an adolescent with chronic pain * able to read and speak german health care professionals group: * health care professional working with adolescents with chronic pain * able to read and speak german exclusion criteria: * no chronic pain or experience with chronic pain
the impact of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies bladder cancer who underwent radical cystectomy

Conditions: Bladder Cancer; Bladder Cancer Stage I; Bladder Cancer Stage II

Summary: the world health organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects on disease management, treatment options, and survival outcomes in bladder tumors with variant histology. in bladder tumors, variant histology is known to be more aggressive and has a worse prognosis than pure urothelial cancer, and most cases are muscle invasive at diagnosis. neoadjuvant cisplatin-containing combination chemotherapy is known to improves overall survival in patients with urothelial cancers. however, it is unclear whether patients with non-pure urothelial cancer (variant) histology will also benefit from neoadjuvant chemotherapy. the investigators aimed to evaluate the role of neoadjuvant cisplatin-containing combination chemotherapy in the final treatment plan and its impact on survival in patients with bladder cancer who were diagnosed with variant histology in the radical cystectomy specimen.


Eligibility criteria:
inclusion criteria: * patients with squamous cell, micropapillary, nested variant, sarcomatoid, neuroendocrine, or plasmacytoid variant histology * patients who were non-metastatic at diagnosis * patients who completed staging and demographic data, * patients with pathological stage (p)t2 or high grade pt1, clinical stage (c)n0 or cn1, and underwent radical cystectomy exclusion criteria: * although rc histopathology was variant histology, patients in whom variant histology was not detected in previously transurethral resection bladder pathology * patients who received therapies other than radical cystectomy (intravesical bacillus-calmette-guerin or chemotherapy) were excluded from the study. * patients with a concomitant diagnosis of upper urinary tract urothelial carcinoma * patients with histopathologically pure urothelial carcinoma

Keywords: bladder cancer variant histology neoadjuvant therapy radical cystectomy
predicting treatment and care difficulties among hiv infected patients

Conditions: HIV

Summary: much of hiv is related to behaviour: sexual risk taking, late diagnosis, adherence to antiretroviral therapy, follow up, disclosure of one's hiv status. the project aimed to use various psychometric tools to determine if these scores have a predictive value on late testing, treatment succes, quality of follow up, and disclosure of hiv to sex partners. the expected outcomes would be to be able to stratify patients using a behavioural risk score and allocate targeted ressources to improve the quality of care for the most at risk patients.


Eligibility criteria:
inclusion criteria: * hiv infected outpatient exclusion criteria: * refusal to participate

Keywords: hiv behavior
neurophysiological and neuropsychological evalution in healthcare workers

Conditions: Stress Disorders, Post-Traumatic

Summary: the goal of this observational study is to compare in participant population the effect of stress condition on cerebral eeg activity participants will do an 8 minutes eeg registration. researchers will compare eeg activity of heathcare workers.


Eligibility criteria:
inclusion criteria: * healthcare workers exclusion criteria: * neurological disorders
de-adoption of beta-blockers in patients with stable ischemic heart disease

Conditions: Stable Ischemic Heart Disease; Coronary Artery Disease; Beta-blocker Therapy

Summary: patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. with newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. the study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. the study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.

patients will be randomized to continue β-blocker therapy or discontinue β-blocker therapy. patients will be followed remotely for approximately four years for adherence, events and outcomes assessments, and completion of multiple web-based quality of life questionnaires.

Eligibility criteria:
inclusion criteria: 1. age \>21 years 2. documented coronary artery disease (cad) defined as: * myocardial infarction at least 6 months prior; or * stable ischemic heart disease (defined using one of the following tests suggestive of significant coronary artery disease): i. positive exercise stress test ii. positive nuclear perfusion scan iii. positive exercise or pharmacologic echocardiographic stress test iv. positive magnetic resonance imaging coronary perfusion scan v. coronary computed tomographic angiography angiogram with stenosis ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing by ct (ffrct); vi. invasive coronary angiography with ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing (ffr) or instant wave free ratio (ifr), * previous percutaneous coronary intervention (pci, at least 6 months prior if revascularization is performed for an mi); or * previous coronary artery bypass grafting (cabg, at least 6 months prior if revascularization is performed for an mi) 3. able and willing to provide informed consent exclusion criteria: 1. left ventricular ejection fraction \< 40% or current hospitalization for heart failure 2. myocardial infarction \<6 months prior to randomization 3. indication for β-blocker as determined by the treating physician (such as atrial or ventricular arrhythmias or ongoing angina not controlled by another agent) 4. uncontrolled hypertension or uncontrolled angina symptoms (per the investigator's discretion) 5. non-compliance with medical therapy 6. life expectancy \<1 year 7. participation in another trial related to β-blockers or other anti-anginal drugs
goniometry and goniometric measurement on standardised images in dupuytren's disease

Conditions: Dupuytren's Disease

Summary: measuring range of motion (rom) is essential in detecting musculoskeletal deficits, monitoring the effects of treatment and progression of the disease. in dupuytren's disease the active and passive extension deficits (aed, ped) of digits 4 and 5 are usually clinically measured using a universal, short arm goniometer which is considered the standard of care. using the goniometer can be time consuming. measuring the extension deficit on a standardised picture could improve follow up, since it is a faster and easier process to take a picture and upload it to the patients files. though this gives rise to the question whether this kind of measurement would be equally accurate and reliable in comparison to regular clinical measurement using a goniometer.

measuring range of motion (rom) is essential in detecting musculoskeletal deficits, monitoring the effects of treatment and progression of the disease. in dupuytren's disease the active and passive extension deficits (aed, ped) of digits 4 and 5 are usually clinically measured using a universal, short arm goniometer which is considered the standard of care. using the goniometer to measure the extension deficit of both fingers, for both the proximal interphalangeal (pip) and metacarpophalangeal (mcp) joint can be a time consuming process. a lot of clinicians have limited time per patient, which leads to partially or completely missing data due to not performing the measurements. measuring the extension deficit on a standardised picture could improve follow up, since it is a faster and easier process to take a picture and upload it to the patients files. though this gives rise to the question whether this kind of measurement would be equally accurate and reliable in comparison to regular clinical measurement using a goniometer. establishing the difference between both methods is essential to monitor change, which makes a statistical comparison of accuracy of both methods very valuable for patients with dupuytren's disease. furthermore, a lot of clinicians have collected and stored standardised pictures of their patient's hands over the years. therefore this study could solidify the available data through these images, which provide valuable information for future follow up. furthermore, proper patient education could provide the clinician with standardised images taken by the patient himself, leading to improved follow up, if images and clinical measurement prove to be equally accurate.

Eligibility criteria:
inclusion criteria: * older than 18 years of age * current aed in digit 4 or 5, in the mcp or pip joint exclusion criteria: * abnormalities to the fingers other than dupuytren's disease which make goniometry impossible (e.g. amputation, arthrodesis of finger joints, deformations due to rheumatoid arthritis etc.) * patient's unable to give a written participating consent. * younger than 18 years of age.
half-normal saline in idiopathic left ventricular outflow tract arrhythmias ablation

Conditions: Ventricular Arrythmia

Summary: the study evaluates the use of half-normal saline as an irrigant for open-irrigated catheters during left ventricular outflow tract ventricular arrhythmias ablation. by increasing the efficacy of radiofrequency energy-mediated lesion formation, half-normal saline has the potential to reduce procedural times and improved acute and long-term outcomes.


Eligibility criteria:
inclusion criteria * male or female between 18 and 75 years of age at the time of enrollment * undergoing first-time radiofrequency ablation for left ventricular outflow tract ventricular arrhythmias * written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study exclusion criteria * ventricular arrhythmias originating from the right ventricular outflow tract according to the ventricular arrhythmia ecg morphology (i.e., precordial r wave transition at v3 or later) * ventricular arrhythmias not originating from cardiac outflow tracts * baseline hyponatremia (serum sodium level \< 135 meq/l) * pregnant, breastfeeding, or unwilling to practice birth control during participation in the study * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
alleviating effects against high intraocular pressure by oral intake of cordyceps cicadae mycelia

Conditions: Supplement

Summary: this study will investigate the effects of lowering intraocular pressure by oral intake of cordyceps cicadae mycelia, to provide evidence-based data for high intraocular pressure relief.

study purpose this study investigated the effeicacy of oral cordyceps cicadae mycelia for the relief of high intraocular pressure. subjects 1. the total recruitment of subjects is 60 people, aged between 20 to 75 years. 2. subjects with intraocular pressure more than or equal to 21 mmhg are included, irrespective of whether on us of taflotan (saflutan). methods 1. informed consents will be obtained from subjects first. the subjects with pre-test intraocular pressure over or equal 21 mm hg are advised to orally take two capsules containing a total of 500 mg of cordyceps cicadae mycelia. after 90 minutes, the subjects are evaluated for intraocular pressure. the pre-test and and post-intake intraocualr pressure and blood pressure data will be compared by paired t test for significant differences if any.

Eligibility criteria:
inclusion criteria: 1. age between 20 and 75 years old, regardless of gender. 2. pre-test confirmation of high intraocular pressure. 3. subjects should understand the trial and agree to join the project. exclusion criteria: 1. age under 20 or over 75 years. 2. use intraocular pressure lowering drugs other than taflotan (saflutan). 3. using beta-blockers or diuretics. 4. being pregnant. 5. disabled individuals with specific diseases or malfunction, for example tumours at terminal stage, blindness. 6. loss of self-consciousness and behavioral capacity. 7. patients with major diseases. withdrawal criteria all subjects may withdraw at any time without any reason. the act of withdraw does not affect rights for them to seek medical advice or treatments.
bronchial artery embolization and medical measures in non severe acute hemoptysis of mild-moderate abundance

Conditions: Hemoptysis; Acute Disease

Summary: severe hemoptysis is a life-threatening condition, with an unpredictable course. the efficacy of bronchial artery embolization (bae) is well established for the treatment of severe hemoptysis, with short and long-term bleeding controls obtained in 70 to 100% and 50 to 90% of cases, respectively. as complications related to vascular interventional radiology may occur in 5 to 10% of cases, the benefit-risk balance might be less clear in acute hemoptysis of mild-to-moderate abundance (volume between 100 and 200 ml) and no criteria of severity (respiratory failure or hemodynamic instability). there is no available data comparing the safety and efficacy of bae combined with medical measures to those of medical measures alone in the treatment of non-severe acute hemoptysis of mild-to-moderate abundance.

the study is a multicentric (n=8) randomized study, involving two parallel groups of patients with non-severe acute hemoptysis of mild-to-moderate abundance, related to a systemic bronchial or non-bronchial hypervascularization, and comparing the bronchial artery embolization combined with medical measures and the medical measures alone in this field. the primary aim of the study is to evaluate the efficacy of bae combined with medical measures in the treatment of non-severe acute hemoptysis of mild-to-moderate abundance, as compared with that of medical measures alone, by assessing the percentage of recurrence of hemoptysis at one month. bleeding recurrence is defined as a volume of blood expectorated of at least 50 ml. the second objectives of the study are to compare the efficacy of the two strategies at 3 months and to assess the safety of both strategies during hospitalization and follow-up. based on a previous study of our group (reference 8), the number of patients in each group is 105, assuming a one-month bleeding recurrence rate of 11% in the group receiving bae, as compared with 26% in the group assisted medically (a=.05; β=0.8).

Eligibility criteria:
inclusion criteria: * non-severe acute hemoptysis (mild-to-moderate abundance and no criteria of severity). * age \> 18 years * patients with social insurance exclusion criteria: * pregnant and/or lactating women * traumatic hemoptysis * severe hemoptysis (volume \> 200 ml; respiratory failure; hemodynamic instability) * patients already enrolled in the study within the preceding 3 months * patients in palliative care, for whom there is no therapeutic plan at short-term * moribund patients

Keywords: bronchial artery embolization non-severe hemoptysis bleeding mild-to-moderate abundance volume ranging from 100 ml to 200 ml